Anti-CGRP Monoclonal Antibodies to Prevent Chronic Migraine (2023 Review)
Migraine, a primary headache disorder, significantly impacts the quality of life of millions worldwide. In recent years, the focus has shifted toward developing targeted therapies, particularly monoclonal antibodies (mAbs) against the calcitonin-gene-related peptide (CGRP), to prevent chronic migraine attacks. A relatively recent comprehensive network meta-analysis (NMA) evaluated the efficacy and safety of various anti-CGRP mAbs, …